Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease
Authors not listed
JHSPH Center for Clinical Trials · 2009
Abstract
The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2009). A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease. <em>JHSPH Center for Clinical Trials</em>. https://clinicaltrials.gov/study/NCT00898807
Vancouver
Anonymous. A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease. JHSPH Center for Clinical Trials. 2009.
BibTeX
@misc{anon2009AMulti,
title = {A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease},
author = {Anonymous},
journal = {JHSPH Center for Clinical Trials},
year = {2009},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Bristol-Myers Squibb 2025
Open access · US-GOV
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 2)
VIVUS LLC 2011
Open access · US-GOV
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
ENCell 2027
Open access · US-GOV
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
Avanir Pharmaceuticals 2012
Open access · US-GOV
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Treeway B.V. 2023
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients
Memory Pharmaceuticals 2005
Open access · US-GOV